Recombinant Human ADAM17 protein is a Human Fragment protein, in the 215 to 671 aa range, expressed in HEK 293, with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, MS, HPLC.
R A D P D P M K N T C K L L V V A D H R F Y R Y M G R G E E S T T T N Y L I E L I D R V D D I Y R N T S W D N A G F K G Y G I Q I E Q I R I L K S P Q E V K P G E K H Y N M A K S Y P N E E K D A W D V K M L L E Q F S F D I A E E A S K V C L A H L F T Y Q D F D M G T L G L A Y V G S P R A N S H G G V C P K A Y Y S P V G K K N I Y L N S G L T S T K N Y G K T I L T K E A D L V T T H E L G H N F G A E H D P D G L A E C A P N E D Q G G K Y V M Y P I A V S G D H E N N K M F S N C S K Q S I Y K T I E S K A Q E C F Q E R S N K V C G N S R V D E G E E C D P G I M Y L N N D T C C N S D C T L K E G V Q C S D R N S P C C K N C Q F E T A Q K K C Q E A I N A T C K G V S Y C T G N S S E C P P P G N A E D D T V C L D L G K C K D G K C I P F C E R E Q Q L E S C A C N E T D N S C K V C C R D L S G R C V P Y V D A E Q K N L F L R K G K P C T V G F C D M N G K C E K R V Q D V I E R F W D F I D Q L S I N T F G K F L A D N
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application MS | Reactivity Reacts | Dilution info - | Notes - |
Application HPLC | Reactivity Reacts | Dilution info - | Notes - |
Transmembrane metalloprotease which mediates the ectodomain shedding of a myriad of transmembrane proteins including adhesion proteins, growth factor precursors and cytokines important for inflammation and immunity (PubMed:24226769, PubMed:24227843, PubMed:28060820, PubMed:28923481). Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form (PubMed:36078095, PubMed:9034191). Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (PubMed:20592283). Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein (PubMed:12441351). Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT) (PubMed:24226769). Plays a role in the proteolytic processing of ACE2 (PubMed:24227843). Plays a role in hemostasis through shedding of GP1BA, the platelet glycoprotein Ib alpha chain (By similarity). Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3 (By similarity). Mediates the proteolytic cleavage of IL6R, leading to the release of secreted form of IL6R (PubMed:26876177, PubMed:28060820). Mediates the proteolytic cleavage and shedding of FCGR3A upon NK cell stimulation, a mechanism that allows for increased NK cell motility and detachment from opsonized target cells. Cleaves TREM2, resulting in shedding of the TREM2 ectodomain (PubMed:28923481).
CD156b, CSVP, TACE, ADAM17, Disintegrin and metalloproteinase domain-containing protein 17, ADAM 17, Snake venom-like protease, TNF-alpha convertase, TNF-alpha-converting enzyme
Recombinant Human ADAM17 protein is a Human Fragment protein, in the 215 to 671 aa range, expressed in HEK 293, with >=95% purity, <= 0.005 EU/µg endotoxin level and suitable for SDS-PAGE, MS, HPLC.
pH: 7.4
Constituents: 10.26% Trehalose, 0.727% Dibasic monohydrogen potassium phosphate, 0.428% Potassium phosphate monobasic
>95% purity determined by SDS-PAGE and HPLC.
Transmembrane metalloprotease which mediates the ectodomain shedding of a myriad of transmembrane proteins including adhesion proteins, growth factor precursors and cytokines important for inflammation and immunity (PubMed:24226769, PubMed:24227843, PubMed:28060820, PubMed:28923481). Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form (PubMed:36078095, PubMed:9034191). Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (PubMed:20592283). Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein (PubMed:12441351). Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT) (PubMed:24226769). Plays a role in the proteolytic processing of ACE2 (PubMed:24227843). Plays a role in hemostasis through shedding of GP1BA, the platelet glycoprotein Ib alpha chain (By similarity). Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3 (By similarity). Mediates the proteolytic cleavage of IL6R, leading to the release of secreted form of IL6R (PubMed:26876177, PubMed:28060820). Mediates the proteolytic cleavage and shedding of FCGR3A upon NK cell stimulation, a mechanism that allows for increased NK cell motility and detachment from opsonized target cells. Cleaves TREM2, resulting in shedding of the TREM2 ectodomain (PubMed:28923481).
The precursor is cleaved by a furin endopeptidase.
For research use only and are not intended for diagnostic or therapeutic use, not for use in humans.
ADAM17 also known as TACE (tumor necrosis factor-alpha converting enzyme) is a metalloprotease belonging to the ADAM (a disintegrin and metalloprotease) family. This protein functions by cleaving and shedding extracellular portions of cell surface proteins. It weighs approximately 93 kDa. ADAM17 is expressed in a range of tissues including the heart liver kidney and brain. The protein plays a role in the regulation of various biological processes through the activation and inactivation of membrane-bound precursor proteins.
The ADAM17 protein regulates a multitude of cellular responses such as inflammation and growth factor signaling. It is not part of a complex but interacts with various substrates in the cell membrane. ADAM17 cleaves precursors to release soluble cytokines and growth factors like tumor necrosis factor-alpha (TNF-alpha) and epidermal growth factor receptor (EGFR) ligands which modulate cell proliferation migration and apoptosis.
ADAM17 plays an integral role in both the TNF and EGFR signaling pathways. These pathways are important in maintaining normal cellular homeostasis. ADAM17 interacts with proteins like TNF receptors and ligands of the EGFR family integrating signaling that affects immune response and cell growth. The regulatory function of ADAM17 in these pathways makes it an important target for modulating cellular responses triggered by external stimuli.
ADAM17 has significant implications in conditions such as rheumatoid arthritis and cancer. In rheumatoid arthritis the protein's shedding activity influences inflammatory cytokines contributing to the disease's pathogenesis alongside proteins like TNF-alpha. In cancer ADAM17's ability to release EGFR ligands affects tumor cell proliferation and metastasis with interactions involving EGFR proteins. It is a target of therapeutic interest with research focused on developing inhibitors to manage these diseases effectively.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
SDS-PAGE analysis of ab282373
Mass determination by ESI-TOF.
Predicted MW 51227.47 is Da (+/- 10 Da by ESI-TOF). Observed MW is 51234.62 Da.
Before running mass spectrometry, deglycosylation was performed to remove glycosylation. This results in a molecular weight of 52 kDa in mass spectrometry.
HPLC analysis of ab282373.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com